[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"perinatal-and-neonatal-outcomes-in-pregnancies-with-type-2-diabetes-mellitus-t2dm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:perinatal-and-neonatal-outcomes-in-pregnancies-with-type-2-diabetes-mellitus-t2dm":53},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":5},"100611487",false,"NCT07241221","Antenatal Myo-inositol Supplementation in Pre-existing Diabetes","Antenatal Myo-inositol Supplementation in Pre-existing Diabetes to Promote Normal Neonatal Outcomes","AMulet","Inclusion Criteria\n\n* Pregnant women aged 21 years to 45 years old at the time of recruitment\n* Ongoing, viable, singleton intrauterine pregnancy\n* Between 12+0 days-16+6 days weeks' gestation at recruitment\n* T2DM diagnosed by a documented 75g Oral Glucose Tolerance Test (OGTT) showing a fasting glucose of \\>7 mmol\u002FL or 2h glucose \\>11.1 mmol\u002FL, or an HbA1C \\>6.5%, either prior to pregnancy or during the first 16 weeks of the index pregnancy\n* Intend to receive antenatal care and give birth at NUH\n* Willing to provide written, informed consent\n* Able to swallow capsules and comply with trial procedures\n\nExclusion Criteria\n\n* Known or suspected fetal aneuploidy or genetic\u002Fstructural anomaly\n* Severe allergy to food items requiring carriage of an Epipen at all times","FEMALE","21 Years","45 Years",{"count":20,"type":21},182,"ESTIMATED","INTERVENTIONAL",[24],"NA","This feasibility pilot study aims to gather data that can guide the design of a larger, more comprehensive trial to establish the effects of myo-inositol supplementation on supporting healthy outcomes in pregnancies complicated by Type 2 Diabetes Mellitus (T2DM). It seeks to assess myo-inositol's potential to support fetal and neonatal health, and optimise maternity outcomes as a complementary approach and adjuvant to existing diabetes mellitus therapies, as well as investigate the underlying biological mechanisms.",[27],"Perinatal and Neonatal Outcomes in Pregnancies With Type 2 Diabetes Mellitus (T2DM)",[29,30,31,32,33,34,35,36,37,38,39,40],"Diabetes","Pregnancy","Myo-inositol","Folic acid","Dietary Supplement","Birthweight","Prematurity","Neonatal Intensive Care Unit Admission","Stillbirth","Neonatal Death","Neonatal Complications","Maternity Complications","RECRUITING","2025-12-02",{"date":44,"type":45},"2025-12-09","ACTUAL",{"date":47,"type":21},"2025-12",{"date":49,"type":21},"2029-08-31",{"name":51,"class":52},"National University Hospital, Singapore","OTHER",""]